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Abstract Bronchiectasis is characterized pathologically by permanent abnormal bronchial dilation, and clinically by
chronic sputum production. Aquaporin 3 (AQP3), a recently described water channel that is also found in large airway
cellmembrane, could play a role in the pathogenesis and particularly that of bronchorrhea in bronchiectasis.However,
little isknownof its in vivo distribution andphysiologicalrole inhuman airways.Wehave, therefore, performedthis quan-
titative immunohistochemistry study on endobronchial biopsies to evaluate the expression and clinical relevance of
AQP3 in patientswith idiopathic bronchiectasis (n= 25,15 F, 64.3711.5 years) and control subjects (n= 14, 5 F, 57.5712.0
years).Quantitativeimage analysiswasperformedto evaluatethe expressionof AQP3 inthebronchialepithelialcells.Our
results show thatAQP3waspredominantlyexpressedinthebasalcellsoftheepitheliallayerinbothgroups.Expressionof
AQP3 was significantly reduced in the basal, but not columnar, epithelial cells in bronchiectasis compared with control
airways (p= 0.02, 0.35).Only bronchiectatic patients with regular sputum production, but not their counterparts, had
significant downregulation of epithelial AQP3 expression comparedwith control airways (p= 0.004, 0.24).Our findings
suggest that AQP3 could have an important role in the pathogenesis of increasedmucus production in bronchiectasis.
r 2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1413, available online at http://www.idealibrary.comon
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Bronchiectasis is a chronic infective and in£ammatory
airway disease characterized pathologically by perma-
nent abnormal dilation of the bronchi, and clinically by
chronic sputumproduction.The pathogenesis of bronch-
iectasis, particularly that of bronchorrhea, is poorly un-
derstood. By controlling transepithelial water
movement, the oropharynx and upper airway mucosa
humidify the inspired air, while the distal airways and
parenchyma mobilize £uid at the time of birth and opti-
mize £uid balance afterwards to ensure that gaseous ex-
change could occur e⁄ciently (1). Disruption in water
£ux at these sitesmay contribute to the pathogenesis of
rhinorrhea, bronchorrhea, or pulmonary edema (2).
Aquaporins (AQPs) are integral membrane proteins,
which act as water channels in a variety of water trans-
porting tissues. Homologs of AQP have also been de-Received 22 January 2002, accepted in revised form 27may 2002.
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SAR,China.Fax: +852 28162863; E-mail: knlai@hkucc.hku.hkscribed in bacteria, yeast, and plants (3). Altogether 10
mammalian AQPs, namely AQP0 to AQP9, have been
identi¢ed, and these display distinct patterns of tissue
distribution and cellular expression (4,5). Immunocyto-
chemistry andmessenger RNA (mRNA) expression stu-
dies of AQPs have revealed that only four of the known
AQPs are present in the rodent airways (6). AQP3, a
water channel that has a high permeability for glycerol,
is expressed predominantly in the plasma membrane of
basal cells in theproximal airways (4^6). AlthoughAQP3
is speci¢cally localized in the rodent airways, little is
known of its in vivo distribution and physiological role in
human airways.We have, therefore, studied endobron-
chial biopsies to evaluate the expression and clinical rele-
vance of AQP3 in patients with bronchiectasis and
control subjects.
METHODS
Subject recruitment
Patients with idiopathic bronchiectasis, diagnosed by
high-resolution computed tomography (HRCT), were
60 RESPIRATORYMEDICINErecruited with written consent (7). Inclusion criteria
were: absence of other unstable diseases; no alteration
inmedication for43months, and ‘‘steady state’’ bronch-
iectasis (8). Spirometry (FEV1 and FVC) was measured
with a SensorMedics 2200 package (SensorMedics,Yorba
Linda,U.S.A.).Thoracic HRCTwas performedwithin the
previous12months using aGeneral Electric Hispeed Ad-
vantage Scanner (9). Bronchiectasis patients with 24h
sputumvolume45ml and their counterpartswere clas-
si¢ed as ‘‘sputum producers’’ and ‘‘non-producers’’, re-
spectively (7). Otherwise healthy subjects that
underwentbronchoscopy for incidental radiographic dis-
covery of presumed unilateral lung cancer were re-
cruited with written informed consent if they had
normal bronchoscopy and spirometry. The institutional
ethics committee approved the study protocol.
Bronchoscopy and endobronchial biopsy
All subjects underwent bronchoscopy using Olympus
BFP20bronchoscopes (Olympus,Tokyo, Japan) andendo-
bronchial biopsies (EBBs) were takenwith Olympus FB15
alligator forceps (Olympus,Tokyo, Japan).Up to six EBBs
were taken from the most severe bronchiectatic seg-
ment and the lower lobes of the radiologically normal
bronchial tree from bronchiectasis and control subjects,
respectively.
Immunohistochemistry processing
EBBswere ¢xedin10% formalin for 2hbefore embedding
in para⁄n. Immunohistological staining for AQP3 (Alo-
mone Laboratories, Jerusalem, Israel) was performed
using a peptide-derived and a⁄nity-puri¢ed rabbit poly-
clonal antibody. Aunique18 AA synthetic peptide, which
had no signi¢cant homology to other eukaryotic pro-
teins, near the carboxyl terminal domain of AQP3 was
selected for antibody production. Immunoblot analysis
in our laboratory had recently validated the speci¢city
of this anti-APQ3 (10).Tissue sections (4mm)were depar-
a⁄nized, gradually rehydrated, and incubated with 0.5%
hydrogen peroxide, 5% goat serum and 5% bovine serum
albumin, before being incubated overnight with anti-
AQP3 (2mg/ml) at 41C. The bound rabbit anti-AQP3
antibody was visualizedusing theDako Envision Plus Sys-
tem (Dako, CA, U.S.A.) with diaminobenzidine as the
substrate to produce a brown color (10).
Quantitation of intensity of AQP3
immunostaining
Immunostaining for AQP3 for all samples was done in
one single experiment and assessed by one observer
blinded to the origin of the sections. Initially, the thresh-
old for each sectionwas set to standardize the luminanceof the incident lightpassing through the section (where 0
is black and 255 is white), using a Leica QWIN Image
Analysis package (Cambridge, England, U.K.) (11). The
mean intensity of each ¢eld was measured using the HSI
(Hue; Saturation; Intensity) mode at 400 . The inten-
sity of AQP3 immunoreactivity was higher when the
gray pixel value was lower, and vice versa. A total of ¢ve
¢elds were sampled per section for each patient.
Statistical analysis
Comparison of groups was made non-parametrically by
using theMann^Whitney rankorder test as distribution
of data was skewed. Multiple comparisons were per-
formed by using theTukey HSD method. The statistical
analysis was performed by using the SPSS package (ver-
sion10.1). A P value ofo0.05 was considered as statisti-
cally signi¢cant.
RESULTS
Patient demography and clinical
characteristics
Twenty-¢ve patients with idiopathic bronchiectasis (15
females; n=13 for sputumproducers) and14 control sub-
jects (5 females) were recruited between September
1999 and February 2001. The lung function, number of
lung lobes a¡ected by bronchiectasis, 24h sputum vo-
lume at steady state, and medications taken by the
bronchiectasis patients are shown inTable 1. Seventeen
of the patients were never smokers, six were ex-smo-
kers for at least 1 year, and two were current smokers.
There was no signi¢cant di¡erence in age, gender distri-
bution, or smoking history between the two subject
groups (P40.05). Most patients had bilateral bronchiec-
tasis, and the biopsied bronchial segments were right
lower (n=9), left lower (n=7), lingula (n=3), rightmiddle
(n=3) and right upper (n=3) lobes.Therewas no signi¢-
cant di¡erence in the aforementioned parameters be-
tween sputum producers and their counterparts
(P40.05, data not shown).
Expression and localization of AQP3 in
bronchiectatic and control airways
Figure1shows the expression andlocalization of AQP3 in
both the control and bronchiectatic airway biopsies.
AQP3was stained as a brown color, whichwas detected
predominantly within the epithelial layer in both control
and bronchiectatic airways. In both groups of tissue,
therewas non-uniformity of staining.The basal epithelial
cells stainedmore intensively than the columnar epithe-
lial cells on qualitative examination (Fig. 1).The intensity
of AQP3 immunoreactivity in the epithelial cells of the
TABLE 1. Clinical characteristics of bronchiectasis and controlpatientswho underwentendobronchial biopsies
Bronchiectasis
(n= 25, F= 15)
Control
(n= 14, F= 5)
P value
Mean7SD Mean7SD
Age 64.3711.5 57.5712.0 0.10
FEV1 (l) 1.470.6 F
FEV1 (% pred) 79.3727.6 F
FVC (l) 2.070.7 F
FVC (% pred) 82.0725.8 F
Numberof lobes a¡ected
bybronchiectasis
2.571.2 F
24 h sputumvolume (ml) 11.476.1 F
Medications takenbypatients
Nil 11 14
Inhaledbronchodilator 6 0
Theophylline 3 0
Allopurinol 2 0
Beta blocker 3 0
Diuretic 1 0
FIG 1. Photomicrographs of immunostaining on bronchial
biopsy specimens obtained from (A) a control subject and (B) a
bronchiectatic patient showing almost exclusive distribution of
aquaporin 3 (stained brown) within the epithelial layer in both
sections.Therewas alsolessintense staininginthebronchiectatic
section. (Scale bar = 2 mm.)
AQUAPORIN 3 INBRONCHIECTASIS 61bronchiectatic was signi¢cantly lower than that for the
control sections (median 58.26710.6, mean 59.577SD
10.57, range 46.80^82.50; 51.60, 23.07^70.20,50.07710.80; P=0.009; Fig. 2). Among the bronchiecta-
sis patients, the intensity of AQP3 immunoreactivity in
the entire epithelium for sputum producers was signi¢-
cantly lower than that obtained from the non-producers
(60.96, 47.14^82.50, 60.70712.41; 54.10, 46.80^63.10,
54.8175.54, P=0.04). While there was a signi¢cantly
lower intensity of AQP3 immunoreactivity in the entire
epithelium for sputumproducers than that in control air-
ways (51.60, 23.07 ^ 70.20, 50.07710.81, P=0.004), there
was no such di¡erence between sputum non-producers
and control subjects (P=0.24).
The intensity of AQP3 immunoreactivity (Fig. 3) in the
columnar epithelial cells (77.37, 72.21^81.22, 76.4772.70)
was signi¢cantly lower than that for the basal cells in
both bronchiectasis (73.33, 41.30^79.25, 72.8377.04,
P=0.005) and control sections (75.47, 56.70 ^ 87.81,
74.9677.00; and 71.46, 35.93^76.06, 69.0778.16 respec-
tively;Po0.001).Therewas a signi¢cantly lower intensity
of AQP3 immunoreactivity in the basal cells of the
bronchiectasis epithelium compared with control sec-
tions (P=0.02). However, there was no signi¢cant di¡er-
ence in the intensity of AQP3 immunoreactivity in the
columnar cells of the bronchiectasis epithelium com-
paredwith control sections (P=0.35).
DISCUSSION
In this study, we have performed quantitative immuno-
histochemistry to assess the protein expression for
AQP3 in endobronchial biopsies taken from subsegmen-
tal bronchi of patients with bronchiectasis and control
subjects. Our results show that bronchial AQP3 is, as
previously reported in rodents and in the single human
study performed on healthy lung tissue (6,12), predomi-
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FIG 2. Scatterplots showing the signi¢cantlylowerintensityof AQP3 immunoreactivity, expressed ashigher valuesingraypixels, in
the bronchial epitheliumof bronchiectasis comparedwith control sections.
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FIG 3. Scatter plots showing the signi¢cantly higher intensity of AQP3 immunoreactivity, expressed as lower values in gray pixels,
withinthe basal than columnarcells of the bronchial epitheliuminboth control andbronchiectasis sections.
62 RESPIRATORYMEDICINEnantly if not exclusively expressed in the epithelial
layer. The results of our quantitative image analysis
showed that AQP3 expression is signi¢cantly higher
in basal than in columnar epithelial cells both in
control and bronchiectatic airways. Expression of AQP3
was signi¢cantly reduced in the basal but not columnar
epithelial cells in bronchiectasis compared with
control airways. Sputum producers, but not their coun-
terparts, had signi¢cant lower epithelial AQP3 expres-sion than control subjects. It therefore appears
that epithelial AQP3 expression is speci¢cally downregu-
lated in bronchiectasis, particularly in those patients
with regular sputum production. This reduction in
AQP3 could be the result of reduced expression or
increased breakdown, and should be investigated in the
future.
Four members of the AQP protein family are
expressed in the rodent airways and lung. AQP3 is
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throughout the nasopharnyx (6,13,14). The other AQPs,
namely AQP1, AQP4 and AQP5 are predominantly situ-
ated on endothelial cell membrane (15), airway basolat-
eral epithelial surface (13,16), and surface of type I
alveolar pneumocytes and upper airway submucosal
glandular epithelium, respectively (6,17).This speci¢c lo-
calization of AQPs suggests that they should be involved
in controlling water movement between the air space,
interstitial, and capillary compartments (4), although
their roles in airway physiology, pleural £uid dynamics,
and edema still remain unexplored. The increased AQP
expression and air spaceFcapillary water permeability
at birth also supports a role for AQPs in neonatal lung
£uid clearance (4).Possible non-water-transporting roles
of AQPs in the lung alsomerit consideration, particularly
as AQP1has already been shown to modulate carbon di-
oxide transport, albeit physiologically unimportant (18).
Similar to the results from rodent studies (6), in the
onlypublishedhuman studyperformedonhealthy human
tissue, AQP3 was localized to basal cells of the pseudos-
trati¢ednasal andbronchial epithelia (12). AQP3 epithelial
expression, sensitive to changes in pH, in basal cells could
account for the rapid shrinkage and water e¥ux in basal
epithelial cells in response to subepithelial osmotic gradi-
ents (19,20).However, a role for AQP3 as a solute channel
and the relevance of this function in human bronchial
epithelial physiology remains to be established (12). Ex-
pression of AQP3 has also been linked to the excessive
mucus production in cystic ¢brosis as cystic ¢brosis
transmembrane conductance regulator, when stimulated
by protein kinase A, activates water permeability in re-
spiratory epithelial cell via AQP3 regulation (21).
Bronchiectasis is a largely idiopathic condition, which
is very common among the Chinese (7). Although the
pathogenesis is poorly understood, it is nevertheless in-
creasingly more apparent that there are interacting in-
£ammatory and infective elements (22). Proteases in
the airways, derived from bacteria such as Pseudomonas
aeruginosa and neutrophils, also play a highly signi¢cant
role in the continued airway in£ammation and destruc-
tion in bronchiectasis (23). Although it has been recently
shown that administration of inhaled corticosteroid
therapy reduces sputum pro-in£ammatory mediator
contents (8), low-dose erythromycin improves lung func-
tion and sputum volume (24), and nebulization of tobra-
mycin reduces sputum Ps. aeruginosa density (25), there
is still no prospect on development of disease-modifying
treatment in bronchiectasis. Such development of e¡ec-
tive pharmacological management in bronchiectasis ob-
viously requires further research in the pathogenesis of
bronchiectasis.
Our ¢nding of downregulation of AQP3 protein ex-
pression in the bronchiectatic epithelium of patients
who are regular sputum producers strongly suggests
that AQP3 could play an important role in the pathogen-esis of increased mucus production in bronchiectasis.
Chronic production and expectoration of copious
amount of sputum in patients with bronchiectasis re-
£ects the superiority of the mucus-secretory over the
water-reabsorption process. While the increased re-
spiratory mucus production in bronchiectasis and cystic
¢brosis is likely to be multi-factorial, downregulation of
AQP3, awater channel, expression could also contribute
to the decreasedreabsorption of water from the luminal
mucus.The exactmechanism for this downregulation for
AQP3 expression inbronchiectasis is obscure atpresent.
Themechanism(s) for epithelial downregulation of AQP3
expression in bronchiectasis is unclear and there is no
published literature to allow an informed speculation.
This abnormal AQP3 downregulation could be an intrin-
sic defect speci¢c to the bronchiectatic airways,
although it is also highly possible that it is the conse-
quence of abundant presence of proteases, pro-in£am-
matory mediators, and bacteria in the bronchiectatic
airways.
Expression of various lungAQPs is a¡ectedby the pre-
sence of keratinocyte growth factor, corticosteroids, and
possibly other hormonal factors (26,27). Keratinocyte
growth factor downregulates AQP5 expression in type I
alveolar cells invitro (26),while administration of corticos-
teroids increases AQP1mRNA and protein expression in
rat pups in vivo (27). Expression of AQ3 mRNA and pro-
tein is upregulated by dexamethasone in human airway
epithelial A549 cell cultures.This upregulation is also ac-
companiedby an increase in cellmembranewaterperme-
ability (28).These ¢ndings might help explain the clinical
e⁄cacy of corticosteroid therapy in reducingmucus pro-
duction in asthma as AQP3 upregulation could increase
reabsorption of water from the secreted £uid, although
anti-in£ammatory actions should also play a predominant
role (28).While these preliminary experiments explore
the possibility of manipulating AQP expression with
known pharmacological agents, there are still no known
novel agents, which could reliably and safely regulate
AQPs. The ability to manipulate AQP expression might
lead to development of novel pharmacological treatment
of bronchorrhea, a distressing symptom to patients with
bronchiectasis.Further studies on therole ofAQPs in the
pathogenesis of bronchiectasis and cystic ¢brosis are,
therefore, indicated.
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